{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:51:02Z","timestamp":1771026662441,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":3443,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ihj.2012.09.002","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T11:15:43Z","timestamp":1347016543000},"page":"497-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ticagrelor: molecular discovery to clinical evidence"],"prefix":"10.1016","volume":"64","author":[{"given":"Nakul","family":"Sinha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2012.09.002_bib1","series-title":"Cardiovascular Diseases \u2013 Prevention and Control","author":"WHO","year":"2001"},{"key":"10.1016\/j.ihj.2012.09.002_bib2","series-title":"Global Atlas on Cardiovascular Disease Prevention and Control","year":"2012"},{"key":"10.1016\/j.ihj.2012.09.002_bib3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(08)60623-6","article-title":"Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data","volume":"371","author":"Xavier","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2012.09.002_bib4","series-title":"Platelets","year":"2007"},{"key":"10.1016\/j.ihj.2012.09.002_bib5","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","article-title":"Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial","volume":"313","author":"Cairns","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2012.09.002_bib6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2012.09.002_bib7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Th\u00e9roux","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2012.09.002_bib8","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/0735-1097(91)90489-V","volume":"18","author":"Wallentin","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2012.09.002_bib9","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2012.09.002_bib10","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2012.09.002_bib11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2012.09.002_bib12","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/eurheartj\/ehm274","article-title":"An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial","volume":"28","author":"Wang","year":"2007","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"10.1016\/j.ihj.2012.09.002_bib13","first-page":"S75","article-title":"Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors","volume":"105","author":"Storey","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ihj.2012.09.002_bib14","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2012.09.002_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2005-869525","article-title":"Preclinical and clinical studies with selective reversible direct P2Y12 antagonists","volume":"31","author":"Van Giezen","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ihj.2012.09.002_bib16","first-page":"S20","article-title":"No significant food effect on the pharmacokinetics of AZD6140, the first reversible oral P2Y12 receptor antagonist, in healthy subjects [abstract PI-39]","volume":"85","author":"Butler","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ihj.2012.09.002_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2125.2010.03669.x","article-title":"Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers","volume":"70","author":"Butler","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ihj.2012.09.002_bib18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2012.09.002_bib19","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"Cannon","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2012.09.002_bib20","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the onset\/offset study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2012.09.002_bib21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies. The respond study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2012.09.002_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the platelet inhibition and patient Outcomes (PLATO) trial","volume":"157","author":"James","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ihj.2012.09.002_bib23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2012.09.002_bib24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2012.09.002_bib25","doi-asserted-by":"crossref","first-page":"d3527","DOI":"10.1136\/bmj.d3527","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised platelet inhibition and patient outcomes (PLATO) trial","volume":"342","author":"James","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ihj.2012.09.002_bib26","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the platelet inhibition and patient outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2012.09.002_bib27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2012.09.002_bib28","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2012.09.002_bib29","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","author":"Steg Ph","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2012.09.002_bib30","author":"Jneid","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2012.09.002_bib31","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483212001435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483212001435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:48:06Z","timestamp":1758080886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483212001435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0019483212001435"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2012.09.002","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor: molecular discovery to clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2012.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}